Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease

 Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease

Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease

Shots:

  • The P-II/III study involves assessing of Troriluzole (qd, PO) vs PBO in 350 patients with mild to mod. AD for up to 48wks.
  • The study missed its co-primary endpoints i.e. ADAS-cog & CDR-SB. The therapy also failed to beat PBO on the 2EPs of hippocampal volume assessed by MRI in the overall population
  • A subgroup analysis of mild AD patients unveils that troriluzole exhibited a nonsignificant numerical difference of a potential benefit @48wks. on both the ADAS-cog and hippocampal volumetric MRI. Further, secondary & exploratory efficacy analyses and biomarker data including NfL, neurogranin, tau and amyloid are still pending and are expected in the coming mos.

Click here ­to­ read full press release/ article | Ref: Biohaven | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post